Marken and Green Cross Labcell Sign MOU

Partnership is aimed at the joint development of life science logistics in Korea and the global development of RFID shipment monitoring technology

 Research Triangle Park, North Carolina, May 31, 2016 — Marken today announced a new alliance with Green Cross LabCell in Korea.  The partnership will expand the global network options for pharma and life science clients who require delivery of biological specimens and diagnostic tools, and will greatly enhance the service available to labs and patients.

Marken is the leading patient-centric supply chain organization and provides solutions and services to the life sciences industry. They were the only logistics company granted permission by the government to deliver the first direct to patient shipment of clinical drug product in Korea during the outbreak of Middle East Respiratory System (MERS). This precedent-setting shipment allowed many patients in South Korea to continue receiving their clinical trial drugs. Green Cross LabCell is the leader in pathological diagnostics, biological sample and infectious substance including Zika, Anti-HCV, Tuberculosis, MERS etc. shipments throughout Korea and serves all the government and private sector hospitals. Also Green Cross LabCell developed own Smart Tag with RFID monitoring system which is on based IoT and able to track Temperature, GPS, Shock (Vibration) in real time bases on each boxes. According to this MOU, Green Cross LabCell’s RFID technology is currently available to apply for Marken customer and plans to expand the RFID technology as well as overseas global services.

Michael Culme-Seymour, Marken’s Vice President Asia Pacific Region, commented on the goals of both organizations, “This is an exciting partnership and represents a new and superior level of service for our clinical trial and life science clients. Through this partnership, Green Cross can extend its service offering from clients in Korea to the global market via Marken. The partnership offers numerous opportunities including joint sales and operations, the development of RFID technology and Clinical Supply Center development.”

Bok-Soo Park, Chief Executive Officer of Green Cross LabCell said, “We expect to create better service for the international businesses in the life sciences industry through Marken’s global network.” He also said, “Through this partnership, we plan to continue expanding to global market customers.”

Marken’s expanding network of Marken offices and Clinical Supply Centers will enable them to work closely with Green Cross to build on and expand services around RFID and GPS technology to improve the constant monitoring of biological shipments. Both companies are planning areas of cooperation around joint logistics, both in Korea and internationally.

About Marken

Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant Clinical Supply Center network and logistic hubs in 43 locations worldwide. Marken’s 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries.  Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.

About Green Cross LabCell

Green Cross LabCell is a biotechnology company newly established in July 2011 based on Cell Therapy, Cell Banking, Clinical Laboratory Service, Central Lab Business and Bio logistics that Green Cross Corporation strategically focuses its energies on. Especially in the world’s first stem cell therapy product was commercialized in Korea in 2011. Green Cross LabCell has selected Natural killer (NK) cell based immune cell therapy that is currently in Phase II clinical trials and stem cell therapy for incurable diseases as the core strategic projects.  We will continue to concentrate our effort on these 5 core business areas to become a global leader.

CONTACT: Christine Noble,, +1 919 474 6890,

Back to Index